Report cover image

Cardiovascular Devices Market Size, Share & Trends Analysis Report By Product (Diagnostic & Monitoring (ECG, Holter), Surgical Devices (Pacemakers, Stents)), By Region (Europe. APAC, MEA), And Segment Forecasts, 2025 - 2030

Published Nov 11, 2024
Length 240 Pages
SKU # GV21020082

Description

Cardiovascular Devices Market Growth & Trends

The global cardiovascular devices market size is anticipated to reach USD 86.36 billion by 2030 and is anticipated to expand at a CAGR of 8.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is significantly influenced by the increasing prevalence of cardiovascular diseases (CVDs) globally. As lifestyle changes and aging populations contribute to higher rates of conditions such as hypertension, heart attacks, and strokes, there is a growing demand for advanced medical technologies. Technological advancements in device design and functionality have led to improved patient outcomes, further driving market growth. The integration of minimally invasive techniques has also gained traction, appealing to both healthcare providers and patients seeking less traumatic treatment options.

Cardiovascular Disease (CVD) ranks among the top medical conditions globally. In May 2024, the CDC reported nearly 702,880 fatalities resulting from heart disease, representing 1 in every 5 deaths. Key factors propelling this market include rapid technological advancements, increased awareness & screening programs, and growth in demand for minimally invasive procedures.

Moreover, supportive government initiatives and funding aimed at enhancing healthcare infrastructure are propelling the market forward. Increased awareness regarding heart health among the general population has resulted in more individuals seeking preventive care and treatment options. Furthermore, the rise in healthcare expenditure across various regions is facilitating access to innovative cardiovascular devices, thereby expanding their adoption in clinical settings. In April 2024, MicroPort CRM introduced its new line of Implantable Cardiac Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds)-ENERGYA and TALENTIA-in Europe. These devices feature Bluetooth connectivity.

Cardiovascular Devices Market Report Highlights
  • Based on product, surgical devices segment held largest revenue share of 68.8% in 2024 by product and is expected to grow at the highest CAGR over the forecast period due to their critical role in the cardiovascular device market, encompassing a wide range of products designed to diagnose, treat, and manage heart-related conditions.
  • The diagnostic & monitoring segment is expected to grow at the fastest CAGR over the forecast period owing to technological advancements, such as miniaturization and integration of AI in diagnostic tools, which can improve accuracy & patient outcomes.
  • Based on region, North America dominated the segment by region with a market share of 47.7% in 2024 due to an advanced healthcare infrastructure, high prevalence of CVDs, and significant R&D investments by regional players.
  • Asia Pacific segment is expected to grow at the fastest CAGR over the forecast period owing to rising healthcare expenditures and government initiatives to improve healthcare infrastructure
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

240 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Cardiovascular Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing prevalence of cardiovascular diseases
3.3.1.2. Technological advancements
3.3.1.3. Aging population
3.3.2. Market restraint analysis
3.3.2.1. Regulatory challenges
3.3.2.2. High cost of development
3.4. Cardiovascular Devices Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.3. Pipeline Analysis
Chapter 4. Cardiovascular Devices: Product Estimates & Trend Analysis
4.1. Cardiovascular Devices Market: Key Takeaways
4.2. Cardiovascular Devices Market: Movement & Market Share Analysis, 2024 & 2030
4.3. Diagnostic and Monitoring Devices
4.3.1. Diagnostic and monitoring devices estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1. ECG
4.3.1.1.1. ECG market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.2. Implantable Cardiac Monitors
4.3.1.2.1. Implantable cardiac monitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.3. Holter Monitors
4.3.1.3.1. Holter monitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.4. Mobile Cardiac Telemetry
4.3.1.4.1. Mobile cardiac telemetry market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.5. MRI
4.3.1.5.1. MRI estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.6. Cardiovascular Ultrasound
4.3.1.6.1. Cardiovascular ultrasound market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.6.2. 2D
4.3.1.6.2.1. 2D market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.6.3. 3D/4D
4.3.1.6.3.1. 3D/4D market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.6.4. Doppler
4.3.1.6.4.1. Doppler market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.7. Cardiac Diagnostic Catheters
4.3.1.7.1. Cardiac diagnostic catheters market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.8. PET Scanner
4.3.1.8.1. PET scanner market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Surgical Devices
4.4.1. Surgical devices market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.1. Cardiac Resynchronization Therapy (CRT)
4.4.1.1.1. Cardiac resynchronization therapy (CRT) market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.1.2. CRT-Defibrillator
4.4.1.1.2.1. CRT-defibrillator market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.1.3. CRT-Pacemaker
4.4.1.1.3.1. CRT-pacemaker market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2. Implantable Cardioverter Defibrillators (ICDs)
4.4.1.2.1. Implantable cardioverter defibrillators (ICDs) market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.2. Single Chamber ICDs
4.4.1.2.2.1. Single chamber ICDs market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.2.3. Dual Chamber ICDs
4.4.1.2.3.1. Dual chamber ICDs market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.3. Pacemakers
4.4.1.3.1. Pacemakers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.3.2. Conventional Pacemakers
4.4.1.3.2.1. Conventional pacemakers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.3.3. Leadless Pacemakers
4.4.1.3.3.1. Leadless pacemakers market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.4. Coronary Stents
4.4.1.4.1. Coronary stents market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.5. Catheters
4.4.1.5.1. Catheters market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.6. Guidewires
4.4.1.6.1. Guidewires market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.7. Cannula
4.4.1.7.1. Cannula market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.8. Valves
4.4.1.8.1. Valves market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.1.9. Occlusion devices
4.4.1.9.1. Occlusion devices market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Cardiovascular Devices Market: Regional Estimates & Trend Analysis by Country and Product
5.1. Regional Dashboard
5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.3. North America
5.3.1. U.S.
5.3.1.1. Key country dynamics
5.3.1.2. Regulatory framework/ reimbursement structure
5.3.1.3. Competitive scenario
5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
5.3.2. Canada
5.3.2.1. Key country dynamics
5.3.2.2. Regulatory framework/ reimbursement structure
5.3.2.3. Competitive scenario
5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Key country dynamics
5.4.1.2. Regulatory framework/ reimbursement structure
5.4.1.3. Competitive scenario
5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Germany
5.4.2.1. Key country dynamics
5.4.2.2. Regulatory framework/ reimbursement structure
5.4.2.3. Competitive scenario
5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. France
5.4.3.1. Key country dynamics
5.4.3.2. Regulatory framework/ reimbursement structure
5.4.3.3. Competitive scenario
5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Italy
5.4.4.1. Key country dynamics
5.4.4.2. Regulatory framework/ reimbursement structure
5.4.4.3. Competitive scenario
5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Spain
5.4.5.1. Key country dynamics
5.4.5.2. Regulatory framework/ reimbursement structure
5.4.5.3. Competitive scenario
5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Norway
5.4.6.1. Key country dynamics
5.4.6.2. Regulatory framework/ reimbursement structure
5.4.6.3. Competitive scenario
5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Sweden
5.4.7.1. Key country dynamics
5.4.7.2. Regulatory framework/ reimbursement structure
5.4.7.3. Competitive scenario
5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8. Denmark
5.4.8.1. Key country dynamics
5.4.8.2. Regulatory framework/ reimbursement structure
5.4.8.3. Competitive scenario
5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Key country dynamics
5.5.1.2. Regulatory framework/ reimbursement structure
5.5.1.3. Competitive scenario
5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. China
5.5.2.1. Key country dynamics
5.5.2.2. Regulatory framework/ reimbursement structure
5.5.2.3. Competitive scenario
5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. India
5.5.3.1. Key country dynamics
5.5.3.2. Regulatory framework/ reimbursement structure
5.5.3.3. Competitive scenario
5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
5.5.4. Australia
5.5.4.1. Key country dynamics
5.5.4.2. Regulatory framework/ reimbursement structure
5.5.4.3. Competitive scenario
5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
5.5.5. South Korea
5.5.5.1. Key country dynamics
5.5.5.2. Regulatory framework/ reimbursement structure
5.5.5.3. Competitive scenario
5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
5.5.6. Thailand
5.5.6.1. Key country dynamics
5.5.6.2. Regulatory framework/ reimbursement structure
5.5.6.3. Competitive scenario
5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Key country dynamics
5.6.1.2. Regulatory framework/ reimbursement structure
5.6.1.3. Competitive scenario
5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
5.6.2. Argentina
5.6.2.1. Key country dynamics
5.6.2.2. Regulatory framework/ reimbursement structure
5.6.2.3. Competitive scenario
5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.6.3. Mexico
5.6.3.1. Key country dynamics
5.6.3.2. Regulatory framework/ reimbursement structure
5.6.3.3. Competitive scenario
5.6.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
5.7. MEA
5.7.1. South Africa
5.7.1.1. Key country dynamics
5.7.1.2. Regulatory framework/ reimbursement structure
5.7.1.3. Competitive scenario
5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
5.7.2. Saudi Arabia
5.7.2.1. Key country dynamics
5.7.2.2. Regulatory framework/ reimbursement structure
5.7.2.3. Competitive scenario
5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
5.7.3. UAE
5.7.3.1. Key country dynamics
5.7.3.2. Regulatory framework/ reimbursement structure
5.7.3.3. Competitive scenario
5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
5.7.4. Kuwait
5.7.4.1. Key country dynamics
5.7.4.2. Regulatory framework/ reimbursement structure
5.7.4.3. Competitive scenario
5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company/Competition Categorization
6.2. Vendor Landscape
6.2.1. List of key distributors and channel partners
6.2.2. Key customers
6.2.3. Key company market share analysis, 2024
6.3. Market Participant Categorization
6.3.1. Abbott
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Product benchmarking
6.3.1.4. Strategic initiatives
6.3.2. GE HealthCare
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Product benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Edwards Lifesciences Corporation
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Product benchmarking
6.3.3.4. Strategic initiatives
6.3.4. W. L. Gore & Associates, Inc.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Siemens Healthcare GmbH
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. BIOTRONIK SE & Co. KG
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Canon Medical Systems Asia Pte. Ltd.
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. B. Braun SE
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. LivaNova PLC
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Cardinal Health
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Medtronic
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Boston Scientific Corporation
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.